An asteroid is approaching Earth at astounding speed

At the initiative of an American scientist of Pakistani descent, a man in Maryland has been living for three days with a pig’s heart on his chest. Naja was the first person in the world to perform an animal heart transplant Genetically modified human breast.

Dr. is a professor of surgery at the Maryland School of Medicine. Mohammad Mohildin’s research led to attempts to perform this surgery. Video To university.

The operation, which was based on Mohiuddin’s initiative, took 9 hours by a team of doctors led by Bartley Griffiths.

The American researcher “was one of the world’s leading experts in transplanting animal organs into the human body, also known as xenotransplantation, and in collaboration with Dr. Bartley Griffiths he established a special program at the university to perform heart surgery in this way. He performed the last transplant surgery.”

Dave Bennett, 57, said the surgeon’s heart is still working, which will open a new avenue for hundreds of thousands of people waiting in long queues to receive traditional surgeries.

Bennett was able to breathe on his own, though he was connected to an artificial heart that pumped half of his blood needs, and doctors planned to slowly “overturn” him.

In a video released by the university, Mohildin said, “I feel very excited that the surgery went so well beyond expectations.”

“We do not see any sign of this member being rejected,” he added. “The move changed the rules of the game and gave hope to tens of thousands of people.”

To close Biography According to the University of Maryland website, he received his MBBS degree from Dove Medical College in Karachi, Pakistan in 1991, and after completing his surgical training at the Civil Hospital there, he moved to the United States.

In his new home, in the 1990s and early 2000s, he received Fellowships from prestigious American universities and centers, including a Fellowship in Alternative Biology and Immunology in the Department of Cardiac Surgery at the University of Pennsylvania Medical Center. Fellowship in Alternative Surgery at the Allegheny University School of Medicine in Pennsylvania, and at the Allegheny University School of Medicine in Pennsylvania.

Mohildin was interested in understanding the role of B lymphocytes in organ transplantation, particularly in the patient’s ability to tolerate syncope, transplantation, and the complexity of immune modulation.

His research in the field of immunology, which helps the body acquire a new organ, is widely used throughout the field of animal transplantation.

Over the past 30 years, the American physician has made numerous contributions to the field of organ transplantation, including more than 120 publications and more than 100 abstracts.

Mohild was instrumental in initiating alternative research programs at the National Heart, Lung and Blood Institute and at the University of Pennsylvania and Rush.

Most recently, he served as head of the Alternative Division at the Cardiac Surgery Research Program and as Chief Scientist at the National Institute of Heart, Lung and Blood of the National Institutes of Health.

In 2005 he served as a faculty member at the University of Pennsylvania in Philadelphia and at Rush University in Chicago.

Washer Report from the University of Maryland Hospitals The idea of ​​transplanting animal organs was attempted in the eighties by transplanting a monkey’s heart into a woman named “Stephanie Fay Buckler”, but she died 20 days later after her immune system rejected the foreign heart. .

In subsequent years, the idea of ​​installing heart valves from pigs was shown to be successful and more popular, and the challenge was to maintain the function of this organ for a long time, which was central to the success of Mokideen’s experiments. Who found his way in human-like baboons.

The trick to making transplant surgeries successful is to adequately control the immune system so that the human body can recognize and accept the donor organ, without suppressing the immune system, leading to serious complications.

Patient Bennett, who does not immediately reject the new organ, will be closely monitored for days and weeks to determine if the transplant will eventually succeed.

The day before the surgery, the patient said, “I’m going to die or have this transplant. I want to live. I know it’s a shot in the dark, but it’s my last option.”

Mohaildin said: “This is the culmination of many years of very complex research to promote this technique in animals with a survival period of more than nine months. There is no cure. “